Earnings Summary

Net Profits
Net Profit Margins



CELULARITY INC’s revenue jumped +Inf% since last year same period to $3.78Mn in the Q2 2022. On a quarterly growth basis, CELULARITY INC has generated -36.38% fall in its revenue since last 3-months.

Net Profits:

CELULARITY INC’s net profit jumped 770.76% since last year same period to $47.83Mn in the Q2 2022. On a quarterly growth basis, CELULARITY INC has generated 176.07% jump in its net profits since last 3-months.

Net Profit Margins:

CELULARITY INC’s net profit margin jumped NaN% since last year same period to 1266.58% in the Q2 2022. On a quarterly growth basis, CELULARITY INC has generated 219.57% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the CELULARITY INC post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

CELULARITY INC’s earning per share (EPS) estimates for the current quarter stand at -0.23 - a 11.54% jump from last quarter’s estimates.

EPS Estimate Current Year:

CELULARITY INC’s earning per share (EPS) estimates for the current year stand at -0.23.

Key Ratios

Key ratios of the CELULARITY INC post its Q3 2022 earnings

Earning Per Share (EPS)
Return on Assets (ROA)
Return on Equity (ROE)


Earning Per Share (EPS):

CELULARITY INC’s earning per share (EPS) fell -92.5% since last year same period to 0.03 in the Q3 2022. This indicates that the CELULARITY INC has generated -92.5% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. CELULARITY INC’s return on assets (ROA) stands at -0.2.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. CELULARITY INC’s return on equity (ROE) stands at -0.11.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Celularity, Inc. headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by developing off-the-shelf placental-derived allogeneic cell therapies, including unmodified natural killer (NK) cells, genetically-modified NK cells, T-cells engineered with a CAR (CAR T-cells), and mesenchymal-like adherent stromal cells (ASCs) targeting indications across cancer, infectious and degenerative diseases. In addition, Celularity develops and manufactures innovative biomaterials also derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it will be able to develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.

170 Park Avenue, Florham Park, NJ, United States, 07932
Robert Joseph Hariri

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*